Enhancing safety of cytomegalovirus-based vaccine vectors by engaging host intrinsic immunity

Emily Marshall, Daniel Malouli, Scott Hansen, Roxanne M. Gilbride, Colette M. Hughes, Abigail B. Ventura, Emily Ainslie, Andrea N. Selseth, Julia C. Ford, David Burke, Craig N. Kreklywich, Jennie Womack, Alfred W. Legasse, Michael Axthelm, Christoph Kahl, Daniel Streblow, Paul T. Edlefsen, Louis Picker, Klaus Frueh

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Rhesus cytomegalovirus (RhCMV)-based vaccines maintain effector memory T cell responses (TEM) that protect ∼50% of rhesus monkeys (RMs) challenged with simian immunodeficiency virus (SIV). Because human CMV (HCMV) causes disease in immunodeficient subjects, clinical translation will depend upon attenuation strategies that reduce pathogenic potential without sacrificing CMV's unique immunological properties. We demonstrate that "intrinsic" immunity can be used to attenuate strain 68-1 RhCMV vectors without impairment of immunogenicity. The tegument proteins pp71 and UL35 encoded by UL82 and UL35 of HCMV counteract cell-intrinsic restriction via degradation of host transcriptional repressors. When the corresponding RhCMV genes, Rh110 and Rh59, were deleted from 68-1 RhCMV (ΔRh110 and ΔRh59), we observed only a modest growth defect in vitro, but in vivo, these modified vectors manifested little to no amplification at the injection site and dissemination to distant sites, in contrast to parental 68-1 RhCMV. ΔRh110 was not shed at any time after infection and was not transmitted to naïve hosts either by close contact (mother to infant) or by leukocyte transfusion. In contrast, ΔRh59 was both shed and transmitted by leukocyte transfusion, indicating less effective attenuation than pp71 deletion. The T cell immunogenicity of ΔRh110 was essentially identical to 68-1 RhCMV with respect to magnitude, TEM phenotype, epitope targeting, and durability. Thus, pp71 deletion preserves CMV vector immunogenicity while stringently limiting vector spread, making pp71 deletion an attractive attenuation strategy for HCMV vectors.

Original languageEnglish (US)
Article numbereaaw2603
JournalScience Translational Medicine
Volume11
Issue number501
DOIs
StatePublished - Jul 17 2019

Fingerprint

Cytomegalovirus Vaccines
Cytomegalovirus
Immunity
Safety
Leukocyte Transfusion
T-Lymphocytes
Simian Immunodeficiency Virus
Macaca mulatta
Epitopes
Mothers
Phenotype
Injections
Growth
Infection
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Enhancing safety of cytomegalovirus-based vaccine vectors by engaging host intrinsic immunity. / Marshall, Emily; Malouli, Daniel; Hansen, Scott; Gilbride, Roxanne M.; Hughes, Colette M.; Ventura, Abigail B.; Ainslie, Emily; Selseth, Andrea N.; Ford, Julia C.; Burke, David; Kreklywich, Craig N.; Womack, Jennie; Legasse, Alfred W.; Axthelm, Michael; Kahl, Christoph; Streblow, Daniel; Edlefsen, Paul T.; Picker, Louis; Frueh, Klaus.

In: Science Translational Medicine, Vol. 11, No. 501, eaaw2603, 17.07.2019.

Research output: Contribution to journalArticle

Marshall, E, Malouli, D, Hansen, S, Gilbride, RM, Hughes, CM, Ventura, AB, Ainslie, E, Selseth, AN, Ford, JC, Burke, D, Kreklywich, CN, Womack, J, Legasse, AW, Axthelm, M, Kahl, C, Streblow, D, Edlefsen, PT, Picker, L & Frueh, K 2019, 'Enhancing safety of cytomegalovirus-based vaccine vectors by engaging host intrinsic immunity', Science Translational Medicine, vol. 11, no. 501, eaaw2603. https://doi.org/10.1126/scitranslmed.aaw2603
Marshall, Emily ; Malouli, Daniel ; Hansen, Scott ; Gilbride, Roxanne M. ; Hughes, Colette M. ; Ventura, Abigail B. ; Ainslie, Emily ; Selseth, Andrea N. ; Ford, Julia C. ; Burke, David ; Kreklywich, Craig N. ; Womack, Jennie ; Legasse, Alfred W. ; Axthelm, Michael ; Kahl, Christoph ; Streblow, Daniel ; Edlefsen, Paul T. ; Picker, Louis ; Frueh, Klaus. / Enhancing safety of cytomegalovirus-based vaccine vectors by engaging host intrinsic immunity. In: Science Translational Medicine. 2019 ; Vol. 11, No. 501.
@article{b38cc8a6cc544e1580b56e07a0da03e1,
title = "Enhancing safety of cytomegalovirus-based vaccine vectors by engaging host intrinsic immunity",
abstract = "Rhesus cytomegalovirus (RhCMV)-based vaccines maintain effector memory T cell responses (TEM) that protect ∼50{\%} of rhesus monkeys (RMs) challenged with simian immunodeficiency virus (SIV). Because human CMV (HCMV) causes disease in immunodeficient subjects, clinical translation will depend upon attenuation strategies that reduce pathogenic potential without sacrificing CMV's unique immunological properties. We demonstrate that {"}intrinsic{"} immunity can be used to attenuate strain 68-1 RhCMV vectors without impairment of immunogenicity. The tegument proteins pp71 and UL35 encoded by UL82 and UL35 of HCMV counteract cell-intrinsic restriction via degradation of host transcriptional repressors. When the corresponding RhCMV genes, Rh110 and Rh59, were deleted from 68-1 RhCMV (ΔRh110 and ΔRh59), we observed only a modest growth defect in vitro, but in vivo, these modified vectors manifested little to no amplification at the injection site and dissemination to distant sites, in contrast to parental 68-1 RhCMV. ΔRh110 was not shed at any time after infection and was not transmitted to na{\"i}ve hosts either by close contact (mother to infant) or by leukocyte transfusion. In contrast, ΔRh59 was both shed and transmitted by leukocyte transfusion, indicating less effective attenuation than pp71 deletion. The T cell immunogenicity of ΔRh110 was essentially identical to 68-1 RhCMV with respect to magnitude, TEM phenotype, epitope targeting, and durability. Thus, pp71 deletion preserves CMV vector immunogenicity while stringently limiting vector spread, making pp71 deletion an attractive attenuation strategy for HCMV vectors.",
author = "Emily Marshall and Daniel Malouli and Scott Hansen and Gilbride, {Roxanne M.} and Hughes, {Colette M.} and Ventura, {Abigail B.} and Emily Ainslie and Selseth, {Andrea N.} and Ford, {Julia C.} and David Burke and Kreklywich, {Craig N.} and Jennie Womack and Legasse, {Alfred W.} and Michael Axthelm and Christoph Kahl and Daniel Streblow and Edlefsen, {Paul T.} and Louis Picker and Klaus Frueh",
year = "2019",
month = "7",
day = "17",
doi = "10.1126/scitranslmed.aaw2603",
language = "English (US)",
volume = "11",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "501",

}

TY - JOUR

T1 - Enhancing safety of cytomegalovirus-based vaccine vectors by engaging host intrinsic immunity

AU - Marshall, Emily

AU - Malouli, Daniel

AU - Hansen, Scott

AU - Gilbride, Roxanne M.

AU - Hughes, Colette M.

AU - Ventura, Abigail B.

AU - Ainslie, Emily

AU - Selseth, Andrea N.

AU - Ford, Julia C.

AU - Burke, David

AU - Kreklywich, Craig N.

AU - Womack, Jennie

AU - Legasse, Alfred W.

AU - Axthelm, Michael

AU - Kahl, Christoph

AU - Streblow, Daniel

AU - Edlefsen, Paul T.

AU - Picker, Louis

AU - Frueh, Klaus

PY - 2019/7/17

Y1 - 2019/7/17

N2 - Rhesus cytomegalovirus (RhCMV)-based vaccines maintain effector memory T cell responses (TEM) that protect ∼50% of rhesus monkeys (RMs) challenged with simian immunodeficiency virus (SIV). Because human CMV (HCMV) causes disease in immunodeficient subjects, clinical translation will depend upon attenuation strategies that reduce pathogenic potential without sacrificing CMV's unique immunological properties. We demonstrate that "intrinsic" immunity can be used to attenuate strain 68-1 RhCMV vectors without impairment of immunogenicity. The tegument proteins pp71 and UL35 encoded by UL82 and UL35 of HCMV counteract cell-intrinsic restriction via degradation of host transcriptional repressors. When the corresponding RhCMV genes, Rh110 and Rh59, were deleted from 68-1 RhCMV (ΔRh110 and ΔRh59), we observed only a modest growth defect in vitro, but in vivo, these modified vectors manifested little to no amplification at the injection site and dissemination to distant sites, in contrast to parental 68-1 RhCMV. ΔRh110 was not shed at any time after infection and was not transmitted to naïve hosts either by close contact (mother to infant) or by leukocyte transfusion. In contrast, ΔRh59 was both shed and transmitted by leukocyte transfusion, indicating less effective attenuation than pp71 deletion. The T cell immunogenicity of ΔRh110 was essentially identical to 68-1 RhCMV with respect to magnitude, TEM phenotype, epitope targeting, and durability. Thus, pp71 deletion preserves CMV vector immunogenicity while stringently limiting vector spread, making pp71 deletion an attractive attenuation strategy for HCMV vectors.

AB - Rhesus cytomegalovirus (RhCMV)-based vaccines maintain effector memory T cell responses (TEM) that protect ∼50% of rhesus monkeys (RMs) challenged with simian immunodeficiency virus (SIV). Because human CMV (HCMV) causes disease in immunodeficient subjects, clinical translation will depend upon attenuation strategies that reduce pathogenic potential without sacrificing CMV's unique immunological properties. We demonstrate that "intrinsic" immunity can be used to attenuate strain 68-1 RhCMV vectors without impairment of immunogenicity. The tegument proteins pp71 and UL35 encoded by UL82 and UL35 of HCMV counteract cell-intrinsic restriction via degradation of host transcriptional repressors. When the corresponding RhCMV genes, Rh110 and Rh59, were deleted from 68-1 RhCMV (ΔRh110 and ΔRh59), we observed only a modest growth defect in vitro, but in vivo, these modified vectors manifested little to no amplification at the injection site and dissemination to distant sites, in contrast to parental 68-1 RhCMV. ΔRh110 was not shed at any time after infection and was not transmitted to naïve hosts either by close contact (mother to infant) or by leukocyte transfusion. In contrast, ΔRh59 was both shed and transmitted by leukocyte transfusion, indicating less effective attenuation than pp71 deletion. The T cell immunogenicity of ΔRh110 was essentially identical to 68-1 RhCMV with respect to magnitude, TEM phenotype, epitope targeting, and durability. Thus, pp71 deletion preserves CMV vector immunogenicity while stringently limiting vector spread, making pp71 deletion an attractive attenuation strategy for HCMV vectors.

UR - http://www.scopus.com/inward/record.url?scp=85069925068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069925068&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aaw2603

DO - 10.1126/scitranslmed.aaw2603

M3 - Article

VL - 11

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 501

M1 - eaaw2603

ER -